Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Other Accumulated Expenses (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Other Accumulated Expenses for 14 consecutive years, with $2.3 million as the latest value for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 78.83% to $2.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Mar 2026, up 78.83% year-over-year, with the annual reading at $6000.0 for FY2025, 98.95% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $2.3 million at Achieve Life Sciences, up from $6000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $2.3 million in Q1 2026, with the low at $6000.0 in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $846235.3, with a median of $693000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 207.11% in 2022, then tumbled 98.95% in 2025.
  • Achieve Life Sciences' Other Accumulated Expenses stood at $403000.0 in 2022, then decreased by 12.9% to $351000.0 in 2023, then surged by 63.25% to $573000.0 in 2024, then tumbled by 98.95% to $6000.0 in 2025, then skyrocketed by 38766.67% to $2.3 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Other Accumulated Expenses are $2.3 million (Q1 2026), $6000.0 (Q4 2025), and $1.8 million (Q3 2025).